Introduction

Fibrodysplasia ossificans progressiva(FOP) is a devastating and a rare genetic disorder whereby soft tissues of the body, such as muscles, tendons, and ligaments, slowly turn into bone, progressively making the body immobile. Known mostly as "stone man syndrome," this disorder affects only one in two million people all around the world, which is responsible for great disability and a sort of shortened lifespan. The relentless progression of FOP leaves those with the disorder in a perpetual state of immobility as their bodies gradually form a second skeleton. 

Since there is no cure, the effect on quality of life is huge, making further research into FOP understanding and treatment very critical. Understanding of the genetic and molecular mechanisms of FOP is quite critical in the development of an effective treatment. This review is focused on the remarkable progress in research into FOP, referring to genetic mutations, pathophysiology, and new approaches for treatment. It will further debate the challenges in developing treatments and the bright future directions that research is taking. In this view, it is vital to highlight the advancements that have been realised in dealing with FOP-affected subjects.¹

Genetic and molecular basis of FOP

FOP is mainly caused by mutations in the ACVR1 gene, which encodes activin A receptor type-1, a paramount protein in the modulation of the bone morphogenetic signalling process. This signalling pathway mainly has a role in regulating how bones grow and develop. In particular, the substitution of histidine for arginine at codon 206 results in overactive bone morphogenetic proteins (BMP) signalling, which is responsible for inappropriate bone formation in soft tissues, a condition termed heterotopic ossification. 

BMP signalling is closely controlled, such that only appropriate bone formation occurs during development and repair under normal conditions. However, this pathway is disrupted by the ACVR1 mutation in FOP patients and leads to excessive bone formation outside the normal skeleton. This extra-skeletal bone formation is not only abnormal but also irreversible and progressively limits movement and function. 

Other gene mutations and epigenetic factors identified by recent studies might explain the variable severity of the condition. While usually the most common cause is the R206H mutation in the ACVR1 gene, hundreds of other mutations have been identified that could influence the course of the disease. Furthermore, recent studies have demonstrated epigenetic modifications that might modulate the severity of FOP, opening new insights into possible therapeutic targets.²

Advances in understanding the pathophysiology of FOP

FOP flare-ups are characterised by painful swelling and rapid bone formation, generally triggered by minor injuries, viral infections, or spontaneous events. The flare-ups of this process were driven by the activation of an inflammatory response coupled to the aberrant BMP signalling pathway. Recent studies have demonstrated that inflammation plays a key role in the initiation and maintenance of flare-ups, in which the pathological process involves immune cells and inflammatory cytokines. It is facilitated by the differentiation of the mesenchymal stem cells into osteoblasts in the case of FOP. 

In a hereditary disorder, this is dysregulated, and the ACVR1 mutation drives excessive activation of osteoblasts to form bone. Furthermore, immune cells, including macrophages, have been identified, which further this aberrant bone growth through the secretion of factors that worsen the disease in a pro-inflammatory manner. Researchers have generated animal models of the disease to understand it better and test any new treatments. Usually, such models employ mice that have been genetically modified to carry the ACVR1 mutation. As such, these models were useful in the evaluation of the efficacy of new therapeutic approaches and the study of FOP progression. These insights from animal models have helped enormously in furthering our understanding of the cellular and molecular mechanisms underlying FOP and have provided a foundation for preclinical testing of potential therapies.³

Current and emerging treatment approaches

Since the mutation in ACVR1 lies at the centre of the pathogenesis of FOP, therapeutic development has also focused on targeting this pathway. The investigations revolve around small molecule inhibitors that particularly block an overactive ACVR1 receptor. The inhibitors would reduce the excessive BMP signalling and lower the formation of ectopic bone. However, one of the major complications in developing such inhibitors is that they may interfere with normal processes of bone growth and repair, which are also driven by BMP signalling. As inflammation is one of the key drivers of FOP flare-ups, anti-inflammatory therapies form a part of the management of the condition. Corticosteroids are powerful anti-inflammatory drugs that are in use to enable the reduction in the severity of flare-ups. 

In addition, nonsteroidal anti-inflammatory drugs are used to treat pain and inflammation. Moreover, newly developed anti-inflammatory drugs targeted to the specific cytokines of the inflammatory response are being studied for their potential use in preventing or mitigating flare-ups. Next-generation gene editing, in particular the technique of CRISPR/Cas9, has the potential to correct the ACVR1 mutation at the gene level, providing a definitive cure for this horrific disease that is FOP. Though this method is still in an experimental phase, there is significant optimism for the future. 

Another line of investigation that is ongoing involves RNA-based therapies such as antisense oligonucleotides to silence genes or, at least reduce mutant ACVR1 gene activity considerably. In this setting, the therapies will specifically target mutant gene product mRNA for elimination from translation into the overactive ACVR1 protein. Another area of promise for the treatment of FOP comprises inhibitors of BMP signalling. These inhibitors would prevent the abnormal activation of the BMP pathway that drives ectopic bone formation in this disorder. 

Several BMP inhibitors are currently under investigation in clinical trials, some with very encouraging results in terms of slowing down disease progression. If these trials are successful, it will be the first for FOP therapy. Besides the strategies outlined above, there is a whole array of other experimental therapies being pursued by researchers. Among them, some focus on dampening the immune response so that inflammatory triggers cannot occur, and thus flares would be prevented. Other novel approaches in this direction include preventing abnormal bone formation by targeting specific molecular pathways involved in the differentiation of mesenchymal stem cells into osteoblasts characteristic of FOP. ⁴

Challenges and future directions in FOP research

One of the greatest challenges to the development of treatments for FOP is the rarity of this disease itself, which complicates the conduct of large clinical trials. The next challenges lie in the design of therapies against such a complex pathway as BMP signalling and in making sure that such interventions may effectively target only pathological processes without interfering with normal bone growth. The chronic nature of FOP and variable disease severity in individual patients preclude the development of standardised treatment protocols. The more substantial our base of knowledge regarding the genetic and molecular basis of FOP, the greater the impetus toward individualised treatment strategies. Individual treatment against the background of patient genetics may achieve better outcomes. 

Gene therapies aimed at correcting nucleotide mutations and modulating the activity of genes involved in the process may present a bright spot of hope for more efficient and specific therapies for FOP. While this research is underway, at the moment, there is no cure for the disease, and treating FOP remains a challenge. Strategies aimed at improving the quality of life of these patients include multidisciplinary care approaches, treating variables that deal not only with the somatic but also with the psychic and social consequences of the disease. Such therapeutic ingredients in the complex care of patients suffering from FOP include physical therapy, pain management, and psychological support. 

Further, new treatments would require much more extensive and further research on the effects of these kinds of treatments to prove long-lasting benefits without harm. Further molecular mechanisms underlying the disease must be researched for more progress to happen in FOP research. Such partnership-driven research is where the key synergy between scientists, clinicians, and advocacy groups can ensure critical innovation and ultimately raise the essential funds to study research. Future research should focus on the identification of biomarkers predictive of disease progression and treatment response to guide the development of more effective therapies.⁵

Summary

Current research in FOP greatly furthers knowledge about the genetic and molecular mechanisms underlying the disease. Now, having identified the primary cause of FOP as being a mutation in the gene ACVR1, we are on the starting line for treatments targeted to correct or inhibit the aberrant BMP signaling pathway. Gene therapy, RNA-based approaches, and BMP inhibitors can also bring new hope for better treatments soon. These research advances provide hope for patients and clinicians currently dealing with the unremitting progression of the disease and for new, more effective treatments for FOP that are on the horizon. Though available present therapies are limited, continuous research efforts open a path to therapies that will greatly improve life quality in individuals suffering from FOP. 

Thus, patient advocacy and research in this area play a key role in the development of new treatments that can afford better relief and, eventually, a cure. Research into FOP has been a classic demonstration of science and medicine applied to one of the most difficult and rare diseases known. If the intricacies of FOP are further determined, we have the potential to break through with changes that will transform lives into the future. One cannot argue with the fact that research enhances patient care and outcomes. Continued support and collaboration might bring us to a place where FOP is not a life sentence anymore.